Using the Immune System to Destroy Cancer
Download this eBook from Drug Discovery News to learn about leading immunotherapy drugs in the pipeline and discover new approaches to immunotherapy drug discovery and delivery.
Immunology
Bright Peak and Ajinomoto collaborate on immunocytokines
Bright Peak Therapeutics and Ajinomoto enter into research collaboration for novel immunocytokines
Asher Bio bursts on the scene with $55M Series A
Asher Bio focuses on cis-targeting technology to precisely target discrete immune cell subtypes
Combatting immune thrombocytopenia in children
First patient has been dosed in Phase 3 avatrombopag study for the treatment of ITP in children
An alliance for drug development
UCLA researchers to select candidates for development with Xencor’s modular XmAb platforms
Gut fungi aid in immune response
Fungi in the gut help in the fight against dangerous blood-borne fungal infections
DiCE Molecules bags $80M in a Series C
The financing will support the progression of DiCE’s IL-17 antagonist into clinical trials
Amgen licenses AMG 634 to MDGH
AMG 634, an investigational treatment for tuberculosis and leprosy, has been licensed to Medicines Development for Global Health
Best of Immuno-oncology
Download DDN’s “Best of Immuno-oncology” ebook to learn more about recent research in cancer immunotherapy. This ebook includes stories about antibody approaches for treating cancer, the potential of CAR-T therapies, precision cancer immunotherapy directed by immune-profiling, and cancer neoepitope discovery.
Why cellular context is vital for genomics and transcriptomics insights (Sanger Institute)
Gosia Trynka, Group Leader at The Sanger Institute and Experimental Science Director at Open Targets, talks about the importance of cellular context for translating genomic and transcriptomic insights into actionable targets.
OSE brings CLEC-1 to AACRR
CLEC-1 is a new therapeutic target for immuno-oncology.
The research program focuses on developing a cancer immunotherapy targeting CLEC-1, a newly identified C-type lectin receptor, to block suppressive functions of myeloid cells and restore antitumor response to T lymphocytes. Suppressive myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T lymphocytes.
